Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt Panel Agrees to Add Xofluza to Flu Drug Stockpile
June 22, 2022
- Kazuhiro Oshima Tapped as Vice Health Minister, Katsufumi Jo as First Councilor for Pharma Industry Promotion
June 22, 2022
- Pemigatinib, Azacitidine, TAK-611 Get Orphan Tag in Japan
June 22, 2022
- Health Minister Defends Govt Purchase Pact for Shionogi’s COVID Pill
June 21, 2022
- Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
June 21, 2022
- MHLW Wants to Boost Preparedness with Proposed Pandemic Response Division: Minister
June 20, 2022
- PMDA Clears All Its Review Targets, Processed Relief Claims at Record Speed in FY2021
June 20, 2022
- Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
June 20, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- As Election Campaigns Begin, Parties Pitch Policies to Bolster Drug Development, Supply Chains
June 17, 2022
- New NIBIOHN Chief Eager to Bridge Void to Develop Innovative Drug Discovery Platform
June 17, 2022
- First Two Vaccine Projects Adopted for SCARDA Funding
June 17, 2022
- Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
- MHLW Proposes KPIs for Creation of Drug Discovery Ecosystem, 3 Other Areas
June 15, 2022
- Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
June 15, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
- MSD and Pfizer COVID Pills Add Anaphylaxis in ADR List: Label Update
June 15, 2022
- MHLW Publishes Guidelines for Evaluating SaMDs Used for Behavioral Modification
June 15, 2022
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…